Last reviewed · How we verify
APHD-002
APHD-002 is a small molecule that targets the SGLT2 receptor.
APHD-002 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Cardiovascular risk reduction in patients with type 2 diabetes.
At a glance
| Generic name | APHD-002 |
|---|---|
| Sponsor | Aphaia Pharma US LLC |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, APHD-002 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. APHD-002's SGLT2 inhibition also has a secondary effect of reducing sodium reabsorption, which may contribute to its cardiovascular benefits.
Approved indications
- Type 2 diabetes
- Cardiovascular risk reduction in patients with type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of hypotension
- Increased risk of acute kidney injury
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APHD-002 CI brief — competitive landscape report
- APHD-002 updates RSS · CI watch RSS
- Aphaia Pharma US LLC portfolio CI